About
Sean Bickerton is a Physician Scientist affiliated with the Department of Pediatrics at the Yale School of Medicine. He holds an MD from Yale School of Medicine (2021). His research focuses on nanomedicine applications in immunology, autoimmune diseases, and infectious disease responses, particularly leveraging nanoparticle technologies for targeted therapy and diagnostic innovation. Key areas include regulatory T cell induction, transplantation tolerance, and SARS-CoV-2 testing strategies.
Research Interests:
- Development of nanoparticle-based systems for controlled drug delivery
- Immunomodulation in autoimmune conditions (e.g., lupus, type 1 diabetes)
- Biomedical applications for SARS-CoV-2 diagnosis and pathogenesis understanding
- Engineering artificial antigen-presenting cells via nanotechnology
Recent Work Trends: His articles emphasize nanoparticle systems for therapeutic delivery (e.g., IL-2/TGF-β co-delivery), saliva-based testing platforms like SalivaDirect, and mechanistic studies of severe COVID-19 immune responses. These contributions bridge basic immunology with translational medicine.
Grants & Advising: While specific grants or advisees are not explicitly listed, his publications indicate collaborative work in NIH-funded projects involving nanoparticle design and clinical translation. Active participation in Yale's pediatric research initiatives is implied through his institutional affiliation.
Labs/Teams: Likely affiliated with Yale's Department of Pediatrics research groups focusing on immunology and nanomedicine, though specific lab names are not mentioned in provided texts.
